Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Ana Llorente-García
1057  Ergebnisse:
Personensuche X
?
1

Impact of the 2018 revised Pregnancy Prevention Programme b..:

Durán, Carlos E. ; Riera-Arnau, Judit ; Abtahi, Shahab...
Frontiers in Pharmacology.  14 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
2

Table2_Impact of the 2018 revised Pregnancy Prevention Prog..:

Carlos E. Durán ; Judit Riera-Arnau ; Shahab Abtahi...
doi:10.3389/fphar.2023.1207976.s005.  , 2023
Link: https://doi.org/10.3389/..
 
?
3

Image2_Impact of the 2018 revised Pregnancy Prevention Prog..:

Carlos E. Durán ; Judit Riera-Arnau ; Shahab Abtahi...
doi:10.3389/fphar.2023.1207976.s002.  , 2023
Link: https://doi.org/10.3389/..
 
?
4

Table3_Impact of the 2018 revised Pregnancy Prevention Prog..:

Carlos E. Durán ; Judit Riera-Arnau ; Shahab Abtahi...
doi:10.3389/fphar.2023.1207976.s006.  , 2023
Link: https://doi.org/10.3389/..
 
?
5

Image1_Impact of the 2018 revised Pregnancy Prevention Prog..:

Carlos E. Durán ; Judit Riera-Arnau ; Shahab Abtahi...
doi:10.3389/fphar.2023.1207976.s001.  , 2023
Link: https://doi.org/10.3389/..
 
?
6

Image3_Impact of the 2018 revised Pregnancy Prevention Prog..:

Carlos E. Durán ; Judit Riera-Arnau ; Shahab Abtahi...
doi:10.3389/fphar.2023.1207976.s003.  , 2023
Link: https://doi.org/10.3389/..
 
?
7

Table1_Impact of the 2018 revised Pregnancy Prevention Prog..:

Carlos E. Durán ; Judit Riera-Arnau ; Shahab Abtahi...
doi:10.3389/fphar.2023.1207976.s004.  , 2023
Link: https://doi.org/10.3389/..
 
?
8

Impact of the 2018 revised Pregnancy Prevention Programme b..:

Carlos E. Durán ; Judit Riera-Arnau ; Shahab Abtahi...
https://www.frontiersin.org/articles/10.3389/fphar.2023.1207976/full.  , 2023
Link: https://doi.org/10.3389/..
 
?
9

Assessment of thyroiditis risk associated with HPV vaccinat..:

Castillo-Cano, Belén ; Martín-Pérez, Mar ; Llorente-García, Ana...
Vaccine.  40 (2022)  33 - p. 4816-4826 , 2022
Link: https://doi.org/10.1016/..
 
?
10

Flecainide and risk of skin neoplasms: Results of a large n..:

Reyes, Carlen ; León-Muñoz, Luz M ; Pistillo, Andrea...
Frontiers in Pharmacology.  13 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
11

Table1_Flecainide and risk of skin neoplasms: Results of a ..:

Carlen Reyes ; Luz M León-Muñoz ; Andrea Pistillo...
doi:10.3389/fphar.2022.1002451.s001.  , 2022
Link: https://doi.org/10.3389/..
 
?
12

Flecainide and risk of skin neoplasms: Results of a large n..:

Carlen Reyes ; Luz M León-Muñoz ; Andrea Pistillo...
https://www.frontiersin.org/articles/10.3389/fphar.2022.1002451/full.  , 2022
Link: https://doi.org/10.3389/..
 
?
13

Table1_Flecainide and risk of skin neoplasms: Results of a ..:

Carlen Reyes ; Luz M León-Muñoz ; Andrea Pistillo...
doi:10.3389/fphar.2022.1002451.s001.  , 2022
Link: https://doi.org/10.3389/..
 
?
14

Papillomavirus vaccination and Guillain-Barre Syndrome amon..:

Martín-Merino, Elisa ; Castillo-Cano, Belen ; Martín-Perez, Mar..
Vaccine.  39 (2021)  31 - p. 4306-4313 , 2021
Link: https://doi.org/10.1016/..
 
?
15

Evaluation of the Risk of Inflammatory Bowel Disease after ..:

Martín-Merino, Elisa ; Castillo-Cano, Belén ; Martín-Pérez, Mar..
Drug Safety.  44 (2021)  4 - p. 455-466 , 2021
Link: https://doi.org/10.1007/..
 
1-15